Flying solo for a change, Sanofi says isatuximab scored an important success in first PhIII myeloma study
Maybe Sanofi can develop a major new oncology drug on its own.
Early Tuesday the pharma giant announced the successful — topline — Phase III outcome …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
